

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WAI YUEN TONG MEDICINE HOLDINGS LIMITED

(位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)

(Stock Code: 897)

POSITIVE PROFIT ALERT

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform shareholders and potential investors of the Company that based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2015, the Group expects that the profit attributable to owners of the parent for the six months ended 30 September 2015 will likely increase substantially by over 300% as compared to the corresponding period in 2014.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Board**”) of Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司*) (the “**Company**”) and together with its subsidiaries, the “**Group**”) wishes to inform shareholders and potential investors of the Company that based on the preliminary review on the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2015, the Group expects that the profit attributable to owners of the parent for the six months ended 30 September 2015 will likely increase substantially by over 300% as compared to the corresponding period in 2014. Such expected increase was mainly attributable to, among other things, the gain on bargain purchase of additional interest in an associate in end of September 2015, despite the decrease in fair value of equity investments and the loss on deemed partial disposal of equity interests in an associate.

**For identification purpose only*

As the Company is still in the course of preparing its interim results for the six months ended 30 September 2015, the information contained in this announcement is only based on the preliminary review on the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2015 which are yet to be finalised. The unaudited consolidated interim results of the Group for the six months ended 30 September 2015 are expected to be announced by the Company before the end of November 2015.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
WAI YUEN TONG MEDICINE HOLDINGS LIMITED
(位元堂藥業控股有限公司*)
Chan Chun Hong, Thomas
Managing Director

Hong Kong, 19 October 2015

As at the date of this announcement, the executive directors of the Company are Mr. Tang Ching Ho, Mr. Chan Chun Hong, Thomas and Ms. Tang Mui Fun and the independent non-executive directors of the Company are Mr. Siu Man Ho, Simon, Mr. Leung Wai Ho, Mr. Cho Wing Mou and Mr. Li Ka Fai, David.

* For identification purpose only